Journal article · 2026

Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma

Georgina Venetia Long, Muhammad Adnan Khattak, Helen J Gogas, Dirk Schadendorf, Ana Arance, Matteo Salvatore Carlino, Piotr Rutkowski, Gareth Rivalland, Antoni Ribas, Janice M. Mehnert, Patrick Alexander Ott, Reinhard Dummer and 17 more

New England Journal of Medicine · Published 11 November 2026 · DOI 10.1056/nejmoa2609762

View at the publisherCite this paper

In brief

“Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma” is a 2026 journal article by Georgina Venetia Long and 28 co-authors, published in New England Journal of Medicine. OpenAlex counts 1 citations as of 18 November 2026, which puts it in the top 9% of works published in 2026 by citations. The publisher's version is not open access, and OpenAlex records no free legal copy.

Citations
1
Most cited in
2026 (1)
Field-weighted impact
2.40
References
29
Authors
29

Abstract

BACKGROUND: Intismeran autogene (intismeran) is an individualized neoantigen therapy that is designed to induce new T-cell responses and expand preexisting T-cell responses against patient-specific tumor neoantigens, which may potentially improve the efficacy of adjuvant therapy in patients with melanoma. METHODS: In this phase 3, double-blind trial, we randomly assigned patients with completely resected stage IIB… Read the full abstract at the publisher.

Excerpt. This paper is not open access.

Cite this paper

Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.

APA 7

Long, G. V., Khattak, M. A., Gogas, H. J., Schadendorf, D., Arance, A., Carlino, M. S., Rutkowski, P., Rivalland, G., Ribas, A., Mehnert, J. M., Ott, P. A., Dummer, R., Queirolo, P., Gebhardt, C., Dutriaux, C., Rojas, C., Chen, Y., Tachiki, L. M. L., Shapira‐Frommer, R., . . . Del Vecchio, M. (2026). Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2609762

MLA 9

Long, Georgina Venetia, et al. “Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma.” New England Journal of Medicine, 2026. https://doi.org/10.1056/nejmoa2609762.

Chicago

Long, Georgina Venetia, Muhammad Adnan Khattak, Helen J Gogas, Dirk Schadendorf, Ana Arance, Matteo Salvatore Carlino, Piotr Rutkowski, et al. 2026. “Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma.” New England Journal of Medicine. https://doi.org/10.1056/nejmoa2609762.

Harvard

Long, G. V. et al. (2026) ‘Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma’, New England Journal of Medicine. doi:10.1056/nejmoa2609762.

IEEE

G. V. Long et al., “Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma,” New England Journal of Medicine, 2026, doi: 10.1056/nejmoa2609762.

BibTeX

@article{long2026intismeran,
  title     = {{Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma}},
  author    = {Long, Georgina Venetia and Khattak, Muhammad Adnan and Gogas, Helen J and Schadendorf, Dirk and Arance, Ana and Carlino, Matteo Salvatore and Rutkowski, Piotr and Rivalland, Gareth and Ribas, Antoni and Mehnert, Janice M. and Ott, Patrick Alexander and Dummer, Reinhard and Queirolo, Paola and Gebhardt, Christoffer and Dutriaux, Caroline and Rojas, Carlos and Chen, Yuanbin and Tachiki, Lisa May Ling and Shapira‐Frommer, Ronnie and Bechter, Oliver Edgar and Sullivan, Ryan J. and Eggermont, Alexander M.M. and Ojalvo, Laureen S. and Brown, Michelle L. Hoffman and Zhang, Jinchun and Grebennik, Dmitri O. and Fukunaga‐Kalabis, Mizuho and Ascierto, Paolo A. and Del Vecchio, Michele},
  journal   = {New England Journal of Medicine},
  year      = {2026},
  doi       = {10.1056/nejmoa2609762},
  url       = {https://doi.org/10.1056/nejmoa2609762}
}

Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)

Topic and keywords

Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management

  • cutaneous melanoma
  • pembrolizumab
  • immune checkpoint inhibitors
  • adjuvant therapy
  • recurrence-free survival
  • distant metastasis-free survival
  • melanoma recurrence
  • combination immunotherapy

Work with this paper

Most-cited papers in Medicine

All highly cited Medicine papers

Questions about this paper

How do I cite this paper in APA style?

Long, G. V., Khattak, M. A., Gogas, H. J., Schadendorf, D., Arance, A., Carlino, M. S., Rutkowski, P., Rivalland, G., Ribas, A., Mehnert, J. M., Ott, P. A., Dummer, R., Queirolo, P., Gebhardt, C., Dutriaux, C., Rojas, C., Chen, Y., Tachiki, L. M. L., Shapira‐Frommer, R., . . . Del Vecchio, M. (2026). Intismeran Autogene plus Pembrolizumab for Resected Stage IIB to IV Melanoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2609762

How many times has this paper been cited?

1 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.

Is this paper free to read?

OpenAlex records no free legal copy. Check your library's access, the authors' pages or a repository, or ask the corresponding author for a copy.

Who wrote this paper?

Georgina Venetia Long, Muhammad Adnan Khattak, Helen J Gogas, Dirk Schadendorf, Ana Arance, Matteo Salvatore Carlino, Piotr Rutkowski, Gareth Rivalland, Antoni Ribas, Janice M. Mehnert, Patrick Alexander Ott, Reinhard Dummer and 17 more.

What is the DOI of this paper?

10.1056/nejmoa2609762, permanently at https://doi.org/10.1056/nejmoa2609762. Sign in and open it from this page.

Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.